These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1484026)

  • 1. Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
    el-Mangoush M; Singh NK
    J Assoc Physicians India; 1992 Jul; 40(7):452-4. PubMed ID: 1484026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM; de Witte T; de Pauw BE; Haanen C
    Neth J Med; 1990 Feb; 36(1-2):19-24. PubMed ID: 2314517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
    Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy.
    Sticklin LA; Dubbelde K; Larson E
    Oncol Nurs Forum; 1989; 16(3):365-9. PubMed ID: 2734216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
    Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
    Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 10. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of low-dose Ara-C regimen on myelodysplastic syndrome (MDS)].
    Kuriyama K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1198-204. PubMed ID: 3164177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
    Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
    Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
    Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
    Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
    Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
    Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
    J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytarabine-induced pericarditis].
    Yamada T; Tsurumi H; Hara T; Sawada M; Oyama M; Moriwaki H
    Rinsho Ketsueki; 1998 Nov; 39(11):1115-20. PubMed ID: 9866424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
    Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
    Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.